DXB - Research & Valuation, page-203

I think the questions investors should ask are

1) Is DXB today worth more than AUD330m? ( I think should be close to 500m)
2) How is this comparing to other Biotechs - comparable valuations (there are a few valued more in a similar situation)
3) What is the management's track record? (Excellent)
4) Commercial viability - (deals already signed and waiting on USA and China)


All investments in stock markets have an element of speculation - not even big caps can guarantee returns/ EPS etc. So as a business trying to develop a drug, first in class, the real question is, is it worth the risk reward?

I have a few other bio stocks and was a bit late to DXB party but I like what I see here - ticks all boxes for me!